The DEA's five-part test to determine 'currently accepted medical use' is flawed, say the plaintiffs. Read more

It’s the latest sign that the world is warming to the health benefits of a plant that for decades has been dismissed as a dangerous drug. Read more

CBD moves from Schedule I to Schedule V, but only for FDA-approved drugs. Everything else is still treated like heroin. Read more

The lawsuit, known as Washington v. Sessions, was brought by five medical cannabis patients. The federal judge sympathized, but had to follow procedural law. Read more

A blockbuster lawsuit in New York could end cannabis prohibition nationwide. Leafly sat down with David Holland, an attorney for the plaintiffs. Read more

A leading veterinary organization is joining the fight to reschedule cannabis in an effort to speed research into the plant’s effects on our furry friends. Read more

Rescheduling cannabis would have dramatically increased costs for smaller players, potentially pushing them out of business. Read more

We've boiled it down to the basics. Read more

The DEA’s announcement that it will remove a major roadblock to cannabis research could spur broader scientific study of a drug already being used to treat conditions in 25 states. Read more

Restricting cannabis as a Schedule I drug is morally indefensible. It’s time to rethink the lack of wisdom of our scheduling system. Read more